Tardive Dyskinesia

Researchers are investigating epilepsy-dyskinesia syndromes, which are rare genetic diseases causing both movement disorders and epilepsy in children. This multinational retrospective survey, supported by the International Parkinson and Movement Disorder Society, aims to collect detailed clinical and molecular data to better understand these conditions. The study focuses on identifying patterns in disease features, progression, and genetic links to improve knowledge and support precision medicine. The study collects previously recorded data from multiple countries, harmonizing information on clinical features, disease progression, age of onset, genetic variants, and coexisting neurological conditions. By standardizing this data, the survey addresses challenges in rare disease research like small, dispersed patient groups and inconsistent protocols. The goal is to build a shared clinical database and analyze how movement and seizure disorders relate at both clinical and molecular levels. Participants are children aged 0 to 18 years with diagnosed movement disorders linked to specific genetic variants. The study reviews existing medical records and genetic information without new treatments or interventions. Researchers will assess the disease spectrum, how movement disorders affect quality of life, and the effectiveness of symptomatic treatments over one year. The study encourages international collaboration to advance understanding and improve care for these rare conditions.

This research aims to evaluate the effectiveness of valbenazine in adults who have tardive dyskinesia TD and remain symptomatic while receiving or after stopping treatment with a vesicular monoamine transporter 2 VMAT2 inhibitor. The study focuses on both clinician- and patient-reported outcomes to better understand how valbenazine may impact TD symptoms. It is a Phase 4, open-label study sponsored by Neurocrine Biosciences. Participants will receive valbenazine capsules orally once daily for 24 weeks. The study involves a single treatment group with no placebo or comparator group. Valbenazine dosing and administration will be monitored throughout the 24-week treatment period. Participants will be assessed at baseline and at Week 24 for changes in abnormal involuntary movements using the Abnormal Involuntary Movement Scale AIMS. Additional evaluations include the Clinical Global Impression of Severity for TD, the Tardive Dyskinesia Impact Scale, and quality of life measures such as the EuroQol-Visual Analogue Scale. The study will monitor safety and efficacy over the 24 weeks of treatment, with total participation lasting approximately this duration.

This research focuses on isolated dystonia, a movement disorder that causes involuntary muscle contractions leading to abnormal twisting movements and postures. Diagnosing dystonia is challenging because there is no biomarker or gold standard test, resulting in frequent misdiagnoses and delays averaging over 10 years. The study aims to clinically validate DystoniaNet, a deep learning platform designed to improve the accuracy and speed of dystonia diagnosis through retrospective and prospective studies. The study consists of two parts retrospective studies will validate DystoniaNets diagnostic ability by comparing patients with dystonia to healthy individuals and to patients with other neurological or non-neurological conditions that mimic dystonia symptoms. The prospective randomized study will test DystoniaNets performance for fast, objective diagnosis in actual clinical settings. The intervention involves using DystoniaNet as a diagnostic test to distinguish dystonia from similar disorders. Participants will undergo clinical evaluations and brain imaging data will be analyzed by the DystoniaNet algorithm to measure the correctness and speed of dystonia diagnosis over four years. Researchers will monitor diagnostic accuracy, time to diagnosis, and compare results across patient groups. This study aims to advance dystonia diagnosis to clinical practice, enabling earlier treatment and better patient outcomes, with participation lasting throughout the study period ending in 2028.

Researchers are evaluating the effects of deutetrabenazine on tardive dyskinesia TD in adults with intellectual and developmental disabilities IDD who have not been previously treated for TD. This open-label Phase 4 study aims to compare treatment responses in this group to published results from patients without IDD. The study will also assess safety, changes in daily living activities, quality of life, and caregiver burden using validated measurement tools. Participants will receive deutetrabenazine oral capsules with doses titrated from 12 mg to 24 mg per day over 24 weeks. Those taking strong CYP2D6 inhibitors will maintain the 24 mg dose throughout. The study involves five visits baseline, 3 weeks, 6 weeks, 12 weeks, and 24 weeks. There is no comparison group instead, responses will be compared to previous research that led to FDA approval. During the study, participants will undergo assessments including the Abnormal Involuntary Movement Scale AIMS, caregiver and clinician global impression scales, and questionnaires measuring activities of daily living, quality of life, caregiver burden, and impact of TD. Researchers will monitor safety, adherence, and treatment effects over the 24-week period. The total involvement includes scheduled visits and evaluations to track changes from baseline through the treatment duration.

Researchers are evaluating the effectiveness of NBI-1065890 compared to a placebo for treating tardive dyskinesia TD in adults. This Phase 2 study focuses on adults aged 18 to 75 with a confirmed diagnosis of TD caused by neuroleptic medication and other related psychiatric conditions such as schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder. The study aims to assess the treatments impact on abnormal involuntary movements and overall improvement. Participants will be randomly assigned to receive either NBI-1065890 or a matching placebo, both taken orally. The study uses a parallel design with quadruple masking to compare the effects over an 8-week period. The main measurement is the change in the Abnormal Involuntary Movement Scale AIMS total score from baseline to week 8, along with secondary assessments of clinical global improvement. During the study, participants will undergo blinded video assessments of their movements, and their responses will be evaluated by expert raters. Researchers will monitor the severity of dyskinesia, psychiatric symptoms, and any side effects. The study includes regular visits over the 8-week treatment period, with safety and tolerability closely observed. Total participation lasts at least 8 weeks, concluding with the final evaluation of movement improvement.

Researchers are studying epilepsy-dyskinesia syndromes, which include movement disorders and seizures linked to genetic causes. This observational study aims to collect long-term clinical data and biological samples from patients of all ages with a confirmed genetic diagnosis. By analyzing molecular and clinical information, the study hopes to uncover patterns that improve understanding of these complex conditions and support precision medicine and international collaboration. Participants will be part of a registry and natural history study where data on clinical features, disease progression, developmental history, functionality, treatment response, and genetic variants will be gathered. Biological samples like blood, urine, and tissue will be collected to establish a biobank. The study is designed to explore genotype-phenotype correlations, assess the impact of symptoms on quality of life, and evaluate treatments over a long period. During the study, participants will undergo regular clinical assessments and provide biological samples to help researchers measure disease characteristics, treatment effects, and quality of life. Outcomes include creating a biorepository, understanding the disease spectrum, assessing treatment effectiveness, and establishing readiness for future clinical trials. The study will last for at least five years, with ongoing monitoring and data collection to support these goals.

This research aims to validate and test the reliability of the Turkish version of the Parkinsons Disease Dyskinesia Scale PDYS-26 for patients with idiopathic Parkinsons disease. Dyskinesia, which involves involuntary muscle movements, is a common motor complication in Parkinsons disease and can affect daily activities. The study evaluates how well this scale measures dyskinesia impact in Turkish-speaking patients and compares it with other assessments like the Tampa Kinesiophobia Scale, Mini BesTest, Activity Specific Balance Safety Scale, and Parkinsons Disease Questionnaire-39. Participants diagnosed with idiopathic Parkinsons disease who have a dyskinesia score of 1 or higher on the Unified Parkinsons Disease Rating Scale UPDRS will be involved. The PDYS-26 scale will be translated into Turkish using a back-translation method and finalized with expert approval. Patients will complete the adapted scale and other related assessments to determine its validity and reliability in the Turkish population. Participants will be assessed at baseline Day 1 and again seven days later Day 8 using the PDYS-26. The study includes evaluations through various questionnaires and scales to measure dyskinesia severity, balance, fear of movement, and quality of life. The research team will monitor the participants responses to ensure the scales effectiveness and relevance for use in clinical settings with Turkish Parkinsons patients.

Researchers are evaluating repetitive transcranial magnetic stimulation rTMS as a treatment for levodopa-induced dyskinesia LID in people with Parkinsons Disease PD. The study focuses on stimulating the pre-supplementary motor area pre-SMA to see if this can delay the start of dyskinesia after levodopa intake and reduce its severity. This research aims to identify the best rTMS targets, parameters, and understand the mechanisms behind LID in PD. Participants will receive rTMS bursts targeting the pre-SMA using a device called the MagVenture Cool-B70 coil. The study includes groups receiving real stimulation at gamma frequency 130Hz or beta frequency 20Hz and corresponding sham inactive stimulations for 30 minutes. The stimulation intensity and location will be optimized based on brain anatomy and electric field simulations. The study compares the effects of these different burst frequencies on LID symptoms. During the study, participants will be assessed using the Unified Dyskinesia Rating Scale UDysRS and monitored for the time dyskinesia begins after taking 150% of their usual morning levodopa dose. Movement symptoms will also be evaluated using the Movement Disorder Society-Unified Parkinsons Disease Rating Scale. A clinician unaware of the treatment group will perform ratings. The study follows a randomized, double-blind design and includes assessments up to 40 minutes after levodopa intake, with safety and response monitored throughout.

Tardive Dyskinesia TD is a movement disorder caused by long-term use of dopamine receptor blockers and related drugs. It results in involuntary movements that persist and cause lasting neurological damage, significantly impacting patients daily functioning. Researchers are evaluating whether repetitive Transcranial Magnetic Stimulation rTMS, a non-invasive brain stimulation technique, can improve motor symptoms in people with TD. This study focuses on a specific rTMS mode called continuous theta-Burst Stimulation cTBS, which may offer more lasting benefits through precise brain targeting. Participants will receive rTMS treatment for 14 days using cTBS. Before treatment, they will undergo an MRI scan to create a personalized brain map, allowing precise localization of the stimulation areas in the motor and sensory networks. The study includes two groups one receiving active rTMS and the other receiving sham placebo rTMS. This design allows comparison to assess the treatments effect on TD motor symptoms under double-blind conditions. During the study, participants will be regularly assessed using the Abnormal Involuntary Movement Scale AIMS over two years to measure changes in abnormal movements. Researchers will monitor safety and treatment effects throughout this period. Participation involves MRI scans, rTMS sessions, and follow-up visits to evaluate motor symptoms and overall response to the intervention.

Researchers are exploring the effects of quitting smoking using varenicline on neurological side effects caused by antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. This 12-week pilot study focuses on 10 smokers with pre-existing tardive dyskinesia who are on stable antipsychotic medication doses. The goal is to find out if stopping smoking with varenicline can reduce these neurological symptoms without worsening other movement-related side effects. Participants will begin the study with a 2-week baseline period to monitor symptoms and smoking habits. Varenicline treatment starts at a low dose and increases over the first two weeks, continuing for the remaining 9 weeks. Participants must stop smoking completely by week 6 and will attend several clinic visits for medication checks and symptom assessments throughout the study. During the study, researchers will regularly assess smoking status using questionnaires and carbon monoxide breath tests. Neurological symptoms will be measured with several rating scales, including the Simpson-Angus Scale and Abnormal Involuntary Movement Scale. Additional evaluations include psychiatric symptoms, cognitive tests, pregnancy tests for women, and monitoring of medication adherence and adverse events. The main outcome is the participants smoking abstinence at 12 weeks, along with changes in smoking amount and neurological side effects.